- Home
- Publications
- Publication Search
- Publication Details
Title
Novel targeted therapies for the management of liver fibrosis
Authors
Keywords
-
Journal
EXPERT OPINION ON EMERGING DRUGS
Volume -, Issue -, Pages 1-12
Publisher
Informa UK Limited
Online
2020-02-26
DOI
10.1080/14728214.2020.1735350
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC
- (2019) Michael Trauner et al. HEPATOLOGY
- Autoimmune hepatitis: current and future therapeutic options
- (2019) Iliana Doycheva et al. LIVER INTERNATIONAL
- THU-093-The calpain inhibitor, BLD-2660, has robust anti-fibrotic activity in a rat model of non-alcoholic steatohepatitis
- (2019) Mozhdeh Sojoodi et al. JOURNAL OF HEPATOLOGY
- GS-06-Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH
- (2019) Zobair Younossi et al. JOURNAL OF HEPATOLOGY
- Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
- (2018) Stephen A. Harrison et al. GASTROENTEROLOGY
- Expression of Fibroblast Growth Factor 21 and β-Klotho Regulates Hepatic Fibrosis through the Nuclear Factor-κB and c-Jun N-Terminal Kinase Pathways
- (2018) Kyong Joo Lee et al. Gut and Liver
- The high burden of alcoholic cirrhosis in privately insured persons in the United States
- (2018) Jessica L. Mellinger et al. HEPATOLOGY
- Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis
- (2018) Oliver Krenkel et al. HEPATOLOGY
- A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
- (2018) Scott L. Friedman et al. HEPATOLOGY
- A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis
- (2018) Kris V. Kowdley et al. HEPATOLOGY
- Safety, tolerability, and pharmacokinetics of BMS-986263/ND-L02-s0201, a novel targeted lipid nanoparticle delivering HSP47 siRNA, in healthy participants: A randomised, placebo-controlled, double-blind, phase 1 study
- (2018) B. Soule et al. JOURNAL OF HEPATOLOGY
- The FXR agonist GS-9674 reduces fibrosis and portal hypertension in a rat model of NASH
- (2018) P. Schwabl et al. JOURNAL OF HEPATOLOGY
- The impact of direct antiviral agent therapy on liver fibrosis in patient with advanced fibrosis related chronic hepatitis C
- (2018) B. Kutala et al. JOURNAL OF HEPATOLOGY
- Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate
- (2018) Benaïssa Boubia et al. JOURNAL OF MEDICINAL CHEMISTRY
- Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis
- (2018) Toshihiro Goto et al. Scientific Reports
- Simtuzumab for Primary Sclerosing Cholangitis: Phase 2 Study Results With Insights on the Natural History of the Disease
- (2018) Andrew J. Muir et al. HEPATOLOGY
- Emricasan (IDN-6556) Lowers Portal Pressure in Patients with Compensated Cirrhosis and Severe Portal Hypertension
- (2018) Guadalupe Garcia-Tsao et al. HEPATOLOGY
- Pharmacological inhibition of CCR2/5 signaling prevents and reverses alcohol-induced liver damage, steatosis and inflammation in mice
- (2018) Aditya Ambade et al. HEPATOLOGY
- Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial
- (2018) Stephen A. Harrison et al. PLoS One
- Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib
- (2018) Saumya Jayakumar et al. JOURNAL OF HEPATOLOGY
- Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial
- (2018) Arun Sanyal et al. LANCET
- Polymer–drug conjugate therapeutics: advances, insights and prospects
- (2018) Iriny Ekladious et al. NATURE REVIEWS DRUG DISCOVERY
- Pegbelfermin (BMS-986036), PEGylated FGF21, in Patients with Obesity and Type 2 Diabetes: Results from a Randomized Phase 2 Study
- (2018) Edgar D. Charles et al. Obesity
- Regression of liver fibrosis over a 24-week period after completing direct-acting antiviral therapy in patients with chronic hepatitis C receiving care within the national hepatitis C elimination program in Georgia
- (2017) Ekaterine Dolmazashvili et al. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY
- Effects of All-Oral Anti-Viral Therapy on HVPG and Systemic Hemodynamics in Patients With Hepatitis C Virus-Associated Cirrhosis
- (2017) Sabela Lens et al. GASTROENTEROLOGY
- Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications
- (2017) Pierre Nahon et al. GASTROENTEROLOGY
- Vascular adhesion protein-1 is elevated in primary sclerosing cholangitis, is predictive of clinical outcome and facilitates recruitment of gut-tropic lymphocytes to liver in a substrate-dependent manner
- (2017) Palak J Trivedi et al. GUT
- Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal
- (2017) Naoki Ikenaga et al. GUT
- Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models
- (2017) Mukul R. Jain et al. LIVER INTERNATIONAL
- Investigating the safety and activity of the use of BTT1023 (Timolumab), in the treatment of patients with primary sclerosing cholangitis (BUTEO): A single-arm, two-stage, open-label, multi-centre, phase II clinical trial protocol
- (2017) Katherine Arndtz et al. BMJ Open
- Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis
- (2017) Giovanni Musso et al. JAMA Internal Medicine
- Randomised clinical study: GR-MD-02, a galectin-3 inhibitor, vs. placebo in patients having non-alcoholic steatohepatitis with advanced fibrosis
- (2016) S. A. Harrison et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: A Nationwide Cohort Study
- (2016) Yi-Wen Huang et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Statins improve NASH via inhibition of RhoA and Ras
- (2016) Robert Schierwagen et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Entering the GOLDEN Age for Therapies in NASH
- (2016) Philip N. Newsome GASTROENTEROLOGY
- Effects of Eradicating Hepatitis C Virus Infection in Patients With Cirrhosis Differ With Stage of Portal Hypertension
- (2016) Vito Di Marco et al. GASTROENTEROLOGY
- Statins Are Associated With a Decreased Risk of Decompensation and Death in Veterans With Hepatitis C–Related Compensated Cirrhosis
- (2016) Arpan Mohanty et al. GASTROENTEROLOGY
- Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis
- (2016) Juan G. Abraldes et al. GASTROENTEROLOGY
- Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
- (2016) Vlad Ratziu et al. GASTROENTEROLOGY
- Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy
- (2016) Jennifer A. Flemming et al. HEPATOLOGY
- Renin–angiotensin system inhibitors and fibrosis in chronic liver disease: a systematic review
- (2016) Gaeun Kim et al. Hepatology International
- Reduction of Liver Steatosis and Fibrosis with an Ask1 Inhibitor in a Murine Model of Nash is Accompanied by Improvements in Cholesterol, Bile Acid and Lipid Metabolism
- (2016) G. Budas et al. JOURNAL OF HEPATOLOGY
- Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index
- (2016) Jacqueline A. Bachofner et al. LIVER INTERNATIONAL
- A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
- (2016) Frederik Nevens et al. NEW ENGLAND JOURNAL OF MEDICINE
- Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells
- (2015) Lee-Won Chong et al. BMC GASTROENTEROLOGY
- Trends in Burden of Cirrhosis and Hepatocellular Carcinoma by Underlying Liver Disease in US Veterans, 2001–2013
- (2015) Lauren A. Beste et al. GASTROENTEROLOGY
- Pathobiology of liver fibrosis: a translational success story
- (2015) Youngmin A Lee et al. GUT
- Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis
- (2015) Siddharth Singh et al. HEPATOLOGY
- AASLD guidelines for treatment of chronic hepatitis B
- (2015) Norah A. Terrault et al. HEPATOLOGY
- Elevated Levels of Endocannabinoids in Chronic Hepatitis C May Modulate Cellular Immune Response and Hepatic Stellate Cell Activation
- (2015) Eleonora Patsenker et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Statin use and non-alcoholic steatohepatitis in at risk individuals
- (2015) Paola Dongiovanni et al. JOURNAL OF HEPATOLOGY
- Hepatic fibrosis: Concept to treatment
- (2015) Christian Trautwein et al. JOURNAL OF HEPATOLOGY
- Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
- (2015) Brent A Neuschwander-Tetri et al. LANCET
- Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C
- (2014) Lucia Flores-Contreras et al. BMC GASTROENTEROLOGY
- Roles for Chemokines in Liver Disease
- (2014) Fabio Marra et al. GASTROENTEROLOGY
- KLF2 exerts antifibrotic and vasoprotective effects in cirrhotic rat livers: behind the molecular mechanisms of statins
- (2014) Giusi Marrone et al. GUT
- Galectin-3 regulates hepatic progenitor cell expansion during liver injury
- (2014) Wei-Chen Hsieh et al. GUT
- Vascular adhesion protein-1 promotes liver inflammation and drives hepatic fibrosis
- (2014) Chris J. Weston et al. JOURNAL OF CLINICAL INVESTIGATION
- Cirrhosis regression in hepatitis C patients with sustained virological response after antiviral therapy: a meta-analysis
- (2014) Ehsaan Akhtar et al. LIVER INTERNATIONAL
- The pan-caspase inhibitor Emricasan (IDN-6556) decreases liver injury and fibrosis in a murine model of non-alcoholic steatohepatitis
- (2014) Fernando J. Barreyro et al. LIVER INTERNATIONAL
- Nuclear control of inflammation and fibrosis in nonalcoholic steatohepatitis: therapeutic potential of dual peroxisome proliferator-activated receptor alpha/delta agonism
- (2013) Pablo Quintero et al. HEPATOLOGY
- Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis
- (2013) Bart Staels et al. HEPATOLOGY
- Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma
- (2013) Bryan C. Fuchs et al. HEPATOLOGY
- Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat
- (2013) Ying-Ying Yang et al. LIVER INTERNATIONAL
- Fibrosis progression in maintenance liver transplant patients with hepatitis C recurrence: a randomised study of everolimus vs. calcineurin inhibitors
- (2013) Federico G. Villamil et al. LIVER INTERNATIONAL
- Therapy of Experimental NASH and Fibrosis with Galectin Inhibitors
- (2013) Peter G. Traber et al. PLoS One
- Regression of Fibrosis and Reversal of Cirrhosis in Rats by Galectin Inhibitors in Thioacetamide-Induced Liver Disease
- (2013) Peter G. Traber et al. PLoS One
- Rimonabant improves obesity but not the overall cardiovascular risk and quality of life; results from CARDIO-REDUSE (CArdiometabolic Risk reDuctIOn by Rimonabant: the Effectiveness in Daily practice and its USE)
- (2012) J. E. J. Boesten et al. FAMILY PRACTICE
- A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis
- (2012) Roberta D'Ambrosio et al. HEPATOLOGY
- Atorvastatin inhibits proliferation and apoptosis, but induces senescence in hepatic myofibroblasts and thereby attenuates hepatic fibrosis in rats
- (2012) Sabine Klein et al. LABORATORY INVESTIGATION
- Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study
- (2012) Patrick Marcellin et al. LANCET
- Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR
- (2012) Anna C. Calkin et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma - a pilot study
- (2011) M. Pinter et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial
- (2011) Claudia O. Zein et al. HEPATOLOGY
- Reversal of liver fibrosis by the antagonism of endocannabinoid CB1 receptor in a rat model of CCl4-induced advanced cirrhosis
- (2011) Ferdinando A Giannone et al. LABORATORY INVESTIGATION
- Long-Term Treatment With Entecavir Induces Reversal of Advanced Fibrosis or Cirrhosis in Patients With Chronic Hepatitis B
- (2010) Eugene R. Schiff et al. Clinical Gastroenterology and Hepatology
- Pharmacokinetics of Oltipraz and Its Major Metabolite (RM) in Patients With Liver Fibrosis or Cirrhosis: Relationship With Suppression of Circulating TGF-β1
- (2010) S G Kim et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration
- (2010) Fatima Teixeira-Clerc et al. HEPATOLOGY
- Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis. A 12-year prospective follow-up study
- (2010) Savino Bruno et al. HEPATOLOGY
- Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B
- (2010) Ting-Tsung Chang et al. HEPATOLOGY
- Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice
- (2010) Marie-Luise Berres et al. JOURNAL OF CLINICAL INVESTIGATION
- New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis
- (2010) Yan Wang et al. JOURNAL OF HEPATOLOGY
- Atorvastatin attenuates hepatic fibrosis in rats after bile duct ligation via decreased turnover of hepatic stellate cells
- (2010) Jonel Trebicka et al. JOURNAL OF HEPATOLOGY
- Hepatic and HSC-specific sorafenib effects in rats with established secondary biliary cirrhosis
- (2010) Martin Hennenberg et al. LABORATORY INVESTIGATION
- Evolving challenges in hepatic fibrosis
- (2010) Scott L. Friedman Nature Reviews Gastroenterology & Hepatology
- Chemokines in Liver Inflammation and Fibrosis
- (2010) Hermann Wasmuth et al. SEMINARS IN LIVER DISEASE
- Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C
- (2009) Jordi Colmenero et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Simvastatin protects against cholestasis-induced liver injury
- (2009) S Dold et al. BRITISH JOURNAL OF PHARMACOLOGY
- T1616 Pan-Caspase Inhibitor VX-166 Reduces Fibrosis in An Animal Model of Non-Alcoholic Steatohepatitis
- (2009) Rafal P. Witek et al. GASTROENTEROLOGY
- Angiotensin II Activates IκB Kinase Phosphorylation of RelA at Ser536 to Promote Myofibroblast Survival and Liver Fibrosis
- (2009) Fiona Oakley et al. GASTROENTEROLOGY
- Farglitazar Lacks Antifibrotic Activity in Patients With Chronic Hepatitis C Infection
- (2009) John McHutchison et al. GASTROENTEROLOGY
- Antagonism of the cannabinoid CB-1 receptor protects rat liver against ischaemia-reperfusion injury complicated by endotoxaemia
- (2009) P. Caraceni et al. GUT
- Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis
- (2009) Guadalupe Garcia-Tsao et al. HEPATOLOGY
- CCR2 promotes hepatic fibrosis in mice
- (2009) Ekihiro Seki et al. HEPATOLOGY
- The regulation of inflammation by galectin-3
- (2009) Neil C. Henderson et al. IMMUNOLOGICAL REVIEWS
- Distinct Roles for Mammalian Target of Rapamycin Complexes in the Fibroblast Response to Transforming Growth Factor-
- (2008) R. A. Rahimi et al. CANCER RESEARCH
- Mechanisms of Hepatic Fibrogenesis
- (2008) Scott L. Friedman GASTROENTEROLOGY
- Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats
- (2008) Marc Mejias et al. HEPATOLOGY
- Farnesoid X receptor antagonizes nuclear factor κB in hepatic inflammatory response
- (2008) Yan-Dong Wang et al. HEPATOLOGY
- Angiotensin receptor blockers are superior to angiotensin-converting enzyme inhibitors in the suppression of hepatic fibrosis in a bile duct-ligated rat model
- (2008) Moon Young Kim et al. JOURNAL OF GASTROENTEROLOGY
- Resolution of liver cirrhosis using vitamin A–coupled liposomes to deliver siRNA against a collagen-specific chaperone
- (2008) Yasushi Sato et al. NATURE BIOTECHNOLOGY
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endocannabinoids and Liver Disease. I. Endocannabinoids and their receptors in the liver
- (2007) A. Mallat et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started